PPARG and fibrosis: Therefore, it raises the topic of combinational therapy in DN in that by synergistically targeting miR-27a/PPARγ/β-catenin and miR-27a/PPARγ/TGF-β signalings, both podocyte injuries and tubulointerstitial fibrosis could be reversed or even prevented.